AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06182878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tender loving care intervention
Description: Receiving weekly prenatal care counseling messages
Study NCT06074848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.
Study NCT06074848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Training
Description: Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.
Study NCT06074848 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Training
Description: Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.
Study NCT06074848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
Study NCT06074848 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training
Description: an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.
Study NCT05940116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20117
Description: Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.~Phase Ib: patients will receive HS-20117 at MED or MAD
Study NCT04722874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-k lenses
Description: Ortho-k lenses will be administered nightly.
Study NCT04722874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses
Description: Ortho-k lenses will be administered nightly.
Study NCT04722874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLRL
Description: RLRL will be performed twice a day with an interval of at least 4 hours, each treatment last 3 minutes. Nightly treatment should be performed at least 30 minutes before ortho-k lens insertion.
Study NCT04844736 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Simulation
Description: Patient will undergo routine CT simulation to initiate radiation treatment planning process. For the purposes of this study, the day of CT simulation mapping scan will be counted as day 0. After the patient completes the CT simulation scan, the CT images and plan/structure files will be sent to the treatment planning system. The treating physician will contour the gross tumor volume (GTV) including the involved primary lung tumor and/or the involved lymph nodes.
Study NCT05539885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-incisional Ultrasound guided (PIFP) block
Description: Patients in group P will be injected with 0.4 mL/kg of 0.25 bupivacaine in the fascial plane between the internal intercostal and pectoralis major muscles on each side of the sternum after induction of anesthesia and before skin incision under ultrasound guidance.
Study NCT05539885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post-incisional Surgeon delivered parasternal block group
Description: After sternal closure, the surgeon will inject bupivacaine (0.5- to 2-mL aliquots depending on the weight) in the fascial plane under direct vision between the 5 anterior (2nd-6th) intercostal spaces on each side 1 to 1.5 cm lateral to the sternal edge using 25-gauge, 50 mm needle. The surgeon will inject the same dose and concentration of bupivacaine used in the ultrasound technique. This technique was prescribed before by Chaudhary et al (23).~In both techniques, the maximum dose of bupivacaine will never be exceeded (2 mg/kg). In addition, all patients were administered 2 mL of 0.25% bupivacaine at the site of the mediastinal drain location.
Study NCT05541146 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Description: Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy
Study NCT05686785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Transient elastography measures liver stiffness in kPa
Study NCT06243692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT06243692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 50Mg Tab
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05229042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ricolinostat
Description: Oral
Study NCT05229042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ricolinostat
Description: Oral
Study NCT05197725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask
Description: Individuals in intervention communities will be given surgical or KF94 face masks.
Study NCT05197725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face mask awareness
Description: Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
Study NCT05197725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face mask promotion through community values or individual information
Description: In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)
Study NCT04679480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab Injection [Libtayo]
Description: Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial.
Study NCT05949294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-SOD1 Injection
Description: single doses of ARO-SOD1 Injection by IT infusion
Study NCT04292184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%
Description: The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
Study NCT05908045 — intervention group
Intervention type: OTHER
Intervention: KAP Survey
Description: This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
Study NCT05811390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: erythritol jet
Description: Use of an erythritol jet in the non-surgical treatment of periimplantitis together with systemic metronidazole
Study NCT05811390 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual instrumentation
Description: Use of manual instrumentation in the non-surgical treatment of periimplantitis together with systemic metronidazole
Study NCT05366790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CEASE and CEASE-A
Description: CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
Study NCT06529510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink therpeutic game
Description: REThink is an online therapeutic game aimed at enhancing the emotional health of young people, grounded in Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who guides players through seven levels, each focused on teaching a specific emotional regulation skill. Each level has three sub-levels that progressively increase in difficulty. REThink can be used as a standalone intervention, an adjunct to self-help psychotherapeutic approaches, or for targeted skills training.
Study NCT05272371 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (Dinutuximab beta in combination with chemotherapy)
Description: Dinutuximab beta in combination with chemotherapy.
Study NCT01222013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
Study NCT04908085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching
Description: Six sessions of OPC delivered by telephone over 10 weeks.
Study NCT04419831 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Stress Pain Test (YSPT)
Description: Yale Stress Pain Test involves 10 minutes exposure to 3 cycles of ice cold bucket hand immersion (stress) or 3 cycles of warm water immersion
Study NCT05510063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira (Adalimumab)
Description: Subcutaneous (SC) injection
Study NCT05510063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira (Adalimumab)
Description: Subcutaneous (SC) injection
Study NCT05510063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB5 (Adalimumab Biosimilar)
Description: Subcutaneous (SC) injection
Study NCT05117736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
Study NCT05117736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.
Study NCT06366178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BONFIX system
Description: The device corresponds to a customized, single-use surgical guide (Class IIa medical device), with a set of different sizes, adapted to the fronto-zygomatic distance (FDZ) measurement, in order to enable better conformation of the orbito-naso-frontal bandeau during surgery for anterior craniostenosis, an ideal conformation that could lead to optimal symmetry and adapted to the morphology of the upper third of infants.~The surgeon conforms the orbito-naso-frontal bandeau by adapting the advancement between the device supports according to the FDZ and then positioning it directly on the surgical guide.
Study NCT05833958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin
Description: As described previously
Study NCT05833958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As described previously - Experimental Arm, 175mg at night
Study NCT05833958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: As described previously - Active Comparator Arm, 500mg in the morning and 500mg at night
Study NCT05512754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: 400 mg tablet
Study NCT04470518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic algorithm
Description: Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache \& Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor)).
Study NCT06073613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral health status
Description: * CSDs medical records: Information related to epidemiological characteristics and chronic inflammatory skin conditions (psoriasis, atopic dermatitis, autoimmune bullous diseases, or systemic lupus erythematosus,...) were recorded from medical records:~  * Pemphigus~ * Mixed connective tissue disease~ * Atopic dermatitis~ * Psoriasis~ * Erythroderma~* oral health status: oral clinical parameters were evaluated:~  * Full mouth bleeding on probing scores~ * Pocket probing depth~ * Clinical attachment level~ * debris index~ * calculus index~ * the number of oral lesions
Study NCT06361563 — intervention group
Intervention type: DRUG
Intervention: Nivolumab
Description: As per product label
Study NCT05142488 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Covid -19 (recombinante) vaccine
Description: Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
Study NCT05142488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covid -19 (recombinante) vaccine
Description: Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
Study NCT05457465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Custom formulation of a hemp-derived, high-CBD product that contains no THC.
Study NCT05909852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501-HCF
Description: Participants will receive a single-dose SC injection of ABP 501-HCF.
Study NCT05909852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 501-LCF
Description: Participants will receive a single-dose SC injection of ABP 501-LCF
Study NCT04718207 — intervention group
Intervention type: DEVICE
Intervention: Brain positron emission tomopgraphy (PET) - scan
Description: Patients who performed brain PET/CT scans in the nuclear medicine department from December 2017 to December 2020.
Study NCT05507307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based pregnancy education program.
Description: Pregnant education program based on mindfulness is planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individu
Study NCT05470335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nurse-led sheath insertion
Description: radial sheaths for coronary examination and intervention are performed by experienced nurses
Study NCT05083000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
Study NCT06217107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Micro-learning content
Description: This is a series of modules designed to provide disease education, additional communication through 'push notifications,' promote self-management, and medication adherence in women of color with lupus and lupus nephritis. Leveraging technology, this program is asynchronous, promotes engagement and retention of information through micro-learning, and allows the investigators to better understand patient experiences beyond structured surveys by capturing what is happening in the patient-coach relationship.
Study NCT06217107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health360x app
Description: The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
Study NCT05571371 — intervention group
Intervention type: OTHER
Intervention: Measuring inflammatory serum biomarkers
Description: Measuring inflammatory serum biomarkers
Study NCT06217107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health360x app
Description: The coach and participant will use problem-solving tools embedded in Health360x to map out potential barriers to goal attainment and create goal action plans. This application has the potential to help improve health-related quality of life, and reduce morbidity and mortality associated with Lupus. The intervention also tests the role of health coaches in the lupus ecosystem. The potential economic gain and impact on more extant social determinants of health can create long ranging benefits on the health and wellbeing of the community.
Study NCT06217107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally congruent coaching
Description: The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
Study NCT06217107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally congruent coaching
Description: The coaching process includes specified visits over the course of our proposed 6-month intervention. These visits will occur remotely using HIPAA compliant video conferencing tools or in person when it is safe and convenient to meet in person. Overall, the coaches will work with Lupus patients to facilitate experiential learning, improve functioning and performance in the context of working towards specific goals.
Study NCT06357403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-factor Xa activity calibrated for enoxaparin
Description: Anti-factor Xa activity calibrated for enoxaparin
Study NCT04752163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1594b
Description: Given DS-1594b PO